Aerpio Pharmaceuticals (OTCMKTS:ARPO) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Aerpio Pharmaceuticals (OTCMKTS:ARPO) from a sell rating to a hold rating in a report published on Thursday morning, Zacks.com reports.

According to Zacks, “Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company’ product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. “

Other equities analysts have also recently issued reports about the company. HC Wainwright assumed coverage on Aerpio Pharmaceuticals in a report on Wednesday, June 12th. They issued a neutral rating and a $1.00 target price for the company. Guggenheim cut Aerpio Pharmaceuticals from a buy rating to a neutral rating in a report on Monday, March 18th. Cantor Fitzgerald set a $8.00 target price on Aerpio Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, March 5th. Finally, National Securities cut Aerpio Pharmaceuticals from a buy rating to a neutral rating in a report on Monday, March 18th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of $6.05.



Aerpio Pharmaceuticals stock opened at $0.97 on Thursday. Aerpio Pharmaceuticals has a 12 month low of $0.88 and a 12 month high of $4.95.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01.

In related news, major shareholder Bioventures Ltd Novartis sold 231,763 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $0.94, for a total transaction of $217,857.22. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 1,750,446 shares of company stock worth $1,774,045. 38.60% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC bought a new position in Aerpio Pharmaceuticals in the 4th quarter valued at $28,000. Bank of New York Mellon Corp bought a new position in Aerpio Pharmaceuticals in the 4th quarter valued at $36,000. Alambic Investment Management L.P. bought a new position in Aerpio Pharmaceuticals in the 1st quarter valued at $85,000. Jane Street Group LLC boosted its position in Aerpio Pharmaceuticals by 216.3% in the 4th quarter. Jane Street Group LLC now owns 81,984 shares of the company’s stock valued at $139,000 after buying an additional 56,065 shares during the last quarter. Finally, HarbourVest Partners LLC bought a new position in Aerpio Pharmaceuticals in the 4th quarter valued at $246,000. Institutional investors and hedge funds own 0.37% of the company’s stock.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

See Also: Call Option Volume

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.